annb0t
Top 20
MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). (PRNewsfoto/Telix Pharmaceuticals Limited)
The results were featured in a late-breaking oral presentation delivered on Sunday, 30 April 2023 (CST) by Associate Profess...
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
The results were featured in a late-breaking oral presentation delivered on Sunday, 30 April 2023 (CST) by Associate Profess...
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
